Physician profile
Eric J Lawrence
NPI 1326223751
$7,073.48
in general payments reported to CMS, 2019-2025
45 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $918 · 2021: $1,111 · 2022: $1,158 · 2023: $976 · 2024: $1,000 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035 · Education: $31.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.89 |
| Education | $31.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,500.26 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $904.54 | 2021-2025 | |
| Lilly USA, LLC | $740.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $651.88 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $603.99 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $441.09 | 2019-2024 | Verquvo, Steglatro, Januvia |
| Otsuka America Pharmaceutical, INC. | $247.08 | 2019-2025 | Rexulti |
| Amgen INC. | $203.40 | 2019-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $181.64 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.49 | 2022-2025 | |
| Pfizer INC. | $172.78 | 2019-2021 | |
| Lundbeck LLC | $89.12 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $78.14 | 2020 | |
| Novartis Pharmaceuticals Corporation | $77.93 | 2019-2025 | |
| Corium, LLC | $67.56 | 2023-2024 | Azstarys |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $59.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.92 | 2019-2024 | Trintellix |
| Exact Sciences Corporation | $58.09 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $54.68 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $50.38 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $49.80 | 2022-2023 | Quviviq |
| Eisai INC. | $48.70 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.80 | 2020-2021 | |
| Abbott Laboratories | $42.78 | 2021-2023 | Freestyle Libre 3 |
| Viatris Specialty LLC | $41.95 | 2025 | Yupelri |
| Mylan Specialty L.P. | $36.73 | 2024 | Yupelri |
| Celgene Corporation | $34.29 | 2022-2023 | Zeposia |
| Neurelis, INC. | $34.20 | 2022-2024 | Valtoco |
| Biogen, INC. | $32.09 | 2021 | |
| Horizon Therapeutics Plc | $31.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.04 | 2022-2023 | Eliquis |
| Axsome Therapeutics, INC. | $21.09 | 2025 | Auvelity |
| Corcept Therapeutics | $20.53 | 2025 | Korlym |
| Ucb, INC. | $19.87 | 2025 | Briviact |
| Sonex Health, INC. | $19.37 | 2025 | Sx-One Microknife |
| Abiomed | $18.74 | 2024 | Impella |
| Dexcom, INC. | $18.28 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $17.70 | 2024 | |
| Vanda Pharmaceuticals INC. | $17.24 | 2025 | Fanapt |
| Organon LLC | $14.94 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.77 | 2021 | |
| Optinose US, INC. | $12.89 | 2021 | |
| Adlon Therapeutics L.P. | $12.77 | 2021 | |
| Philips North America LLC | $12.47 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $7.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.